The relationship between using estrogen and/or progesterone and the risk of mammary gland hyperplasia in women: a meta-analysis

References

• Gou WJ, Zhao JZ, Zhang R, et al. A menopause survey of women with benign breast disease history in northwest China. Climacteric. 2019;22(6):622–626.
   PubMedGoogle Scholar
• Rohan TE, Negassa A, Chlebowski RT, et al. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst. 2008;100(8):563–571.
   PubMedGoogle Scholar
• Rohan TE, Negassa A, Chlebowski RT, et al. Estrogen plus progestin and risk of benign proliferative breast disease. Cancer Epidemiol Biomarkers Prev. 2008;17(9):2337–2343.
   PubMedGoogle Scholar
• Cui Y, Page DL, Lane DS, et al. Menstrual and reproductive history, postmenopausal hormone use, and risk of benign proliferative epithelial disorders of the breast: a cohort study. Breast Cancer Res Treat. 2009;114(1):113–120.
   PubMedGoogle Scholar
• Li HT, Liu HH, Yang YX, et al. Therapeutic effects of a traditional Chinese medicine formula plus tamoxifen vs. Tamoxifen for the treatment of mammary gland hyperplasia: a meta-analysis of randomized trials. Front Pharmacol. 2018;9:45.
   PubMedGoogle Scholar
• Román M, Louro J, Posso M, et al. Breast density, benign breast disease, and risk of breast cancer over time. Eur Radiol. 2021;31(7):4839–4847.
   PubMedGoogle Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
   PubMed Web of Science ®Google Scholar
• Formoso G, Perrone E, Maltoni S, et al. Short and long term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2016;10(10):CD008536.
   PubMedGoogle Scholar
• Ward K, Deneris A. An update on menopause management. J Midwifery Womens Health. 2018;63(2):168–177.
   PubMedGoogle Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s health initiative randomized controlled trial. JAMA. 2004;291(14):1701–1712.
   PubMed Web of Science ®Google Scholar
• Finlay-Schultz J, Sartorius CA. Steroid hormones, steroid receptors, and breast cancer stem cells. J Mammary Gland Biol Neoplasia. 2015;20(1–2):39–50.
   PubMedGoogle Scholar
• Friedenreich C, Bryant H, Alexander F, et al. Risk factors for benign proliferative breast disease. Int J Epidemiol. 2000;29(4):637–644.
   PubMedGoogle Scholar
• Samoli E, Trichopoulos D, Lagiou A, et al. The hormonal profile of benign breast disease. Br J Cancer. 2013;108(1):199–204.
   PubMedGoogle Scholar
• Stanczyk FZ, Winer SA. Effect of hormone therapy on breast epithelial cell proliferation. Menopause. 2013;20(5):483–485.
   PubMedGoogle Scholar
• Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med. 1999;130(4 Pt 1):262–269.
   PubMedGoogle Scholar
• Conner P. Breast response to menopausal hormone therapy-aspects on proliferation, apoptosis and mammographic density. Ann Med. 2007;39(1):28–41.
   PubMed Web of Science ®Google Scholar
• You Z, Sun J, Xie F, et al. Modulatory effect of fermented papaya extracts on mammary gland hyperplasia induced by estrogen and progestin in female rats. Oxid Med Cell Longev. 2017;2017:8235069.
   PubMedGoogle Scholar
• Rohan TE, L’Abbé KA, Cook MG. Oral contraceptives and risk of benign proliferative epithelial disorders of the breast. Int J Cancer. 1992;50(6):891–894.
   PubMedGoogle Scholar
• Winkler UH, Schindler AE, Brinkmann US, et al. Cyclic progestin therapy for the management of mastopathy and mastodynia. Gynecol Endocrinol. 2001;15( 6):37–43.
   PubMedGoogle Scholar
• Reeves GK, Beral V, Green J, et al. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and Meta-analysis. Lancet Oncol. 2006;7(11):910–918.
   PubMedGoogle Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159–1168.
   PubMed Web of Science ®Google Scholar
• Liu C. Advances in the pathogenesis of breast hyperplasia. Medical Review. 2012;18(5):704–706.
   Google Scholar
• Li X, Xin P, Wang C, et al. Mechanisms of traditional Chinese medicine in the treatment of mammary gland hyperplasia. Am J Chin Med. 2017;45(3):443–458.
   PubMed Web of Science ®Google Scholar
• Ma D, Liu G, Zhang X, et al. Massage treatment of hyperplasia of mammary glands: a protocol for a systematic review and meta-analysis. Medicine. 2020;99(52):e23601.
   PubMedGoogle Scholar
• McTiernan A, Martin CF, Peck JD, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: women’s health initiative randomized trial. J Natl Cancer Inst. 2005;97(18):1366–1376.
   PubMedGoogle Scholar
• Conner P, Christow A, Kersemaekers W, et al. A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolon and continuous combined estrogen-progestogen treatment. Climacteric. 2004;7(1):50–58.
   PubMed Web of Science ®Google Scholar
• Silvera SA, Rohan TE. Benign proliferative epithelial disorders of the breast: a review of the epidemiologic evidence. Breast Cancer Res Treat. 2008;110(3):397–409.
   PubMedGoogle Scholar
• Macon MB, Fenton SE. Endocrine disruptors and the breast: early life effects and later life disease. J Mammary Gland Biol Neoplasia. 2013;18(1):43–61.
   PubMed Web of Science ®Google Scholar
• Rohan TE, Miller AB. A cohort study of oral contraceptive use and risk of benign breast disease. Int J Cancer. 1999;82(2):191–196.
   PubMed Web of Science ®Google Scholar
• Schairer C, Hill D, Sturgeon SR, et al. Serum concentrations of estrogens, sex hormone binding globulin, and androgens and risk of breast hyperplasia in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1660–1665.
   PubMedGoogle Scholar